Literature DB >> 18949540

The nurse's role in the prevention of cervical cancer among underserved and minority populations.

Norma Martinez Rogers1, Adelita G Cantu.   

Abstract

Since the implementation of the Papanicolaou test, there has been a significant decline in the incidence of cervical cancer over the last 50 years. Despite this reduction, each year there are approximately 11,000 women in the United States diagnosed with cervical cancer, the second most common type of cancer in women worldwide. Infection with oncogenic human papillomavirus (HPV) is necessary for the development of precancerous lesions and the progression to cervical cancer. For those diagnosed with an HPV infection or cervical cancer, a considerable personal and financial burden often results. Recent analyses estimate that the total direct costs associated with cervical dysplasia and cancer are extensive. Additionally, a patient's quality of life (social, emotional, and sexual functioning) is adversely affected following a diagnosis with an HPV infection or cervical cancer. The data also show disparities in the incidence of cervical cancer and barriers that may contribute to these phenomena in underserved populations. National programs have been implemented and can help reduce the burden of disease, but vaccination against HPV remains the primary method of prevention. In the healthcare field, nurses play many roles, a prominent one being a patient educator. As a result, there is a need to educate nurses about the risks and impact of HPV and cervical cancer. Nurses can be instrumental in educating the public about vaccination and increasing awareness of HPV and cervical cancer among the underserved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 18949540     DOI: 10.1007/s10900-008-9134-4

Source DB:  PubMed          Journal:  J Community Health        ISSN: 0094-5145


  60 in total

Review 1.  Links between innate and adaptive immunity via type I interferon.

Authors:  Agnes Le Bon; David F Tough
Journal:  Curr Opin Immunol       Date:  2002-08       Impact factor: 7.486

Review 2.  Review of the economic and quality-of-life burden of cervical human papillomavirus disease.

Authors:  Rachael L Fleurence; Julia M Dixon; Tsveta F Milanova; Kathleen M Beusterien
Journal:  Am J Obstet Gynecol       Date:  2007-03       Impact factor: 8.661

Review 3.  Immune responses to human papillomavirus.

Authors:  Margaret Stanley
Journal:  Vaccine       Date:  2006-03-30       Impact factor: 3.641

4.  Enhanced humoral and memory B cellular immunity using HPV16/18 L1 VLP vaccine formulated with the MPL/aluminium salt combination (AS04) compared to aluminium salt only.

Authors:  Sandra L Giannini; Emmanuel Hanon; Philippe Moris; Marcelle Van Mechelen; Sandra Morel; Francis Dessy; Marc A Fourneau; Brigitte Colau; Joann Suzich; Genevieve Losonksy; Marie-Thérèse Martin; Gary Dubin; Martine A Wettendorff
Journal:  Vaccine       Date:  2006-06-19       Impact factor: 3.641

5.  Worldwide human papillomavirus etiology of cervical adenocarcinoma and its cofactors: implications for screening and prevention.

Authors:  Xavier Castellsagué; Mireia Díaz; Silvia de Sanjosé; Nubia Muñoz; Rolando Herrero; Silvia Franceschi; Rosanna W Peeling; Rhoda Ashley; Jennifer S Smith; Peter J F Snijders; Chris J L M Meijer; F Xavier Bosch
Journal:  J Natl Cancer Inst       Date:  2006-03-01       Impact factor: 13.506

Review 6.  Can glandular lesions be diagnosed in pap smear cytology?

Authors:  S S Raab
Journal:  Diagn Cytopathol       Date:  2000-08       Impact factor: 1.582

7.  International trends in incidence of cervical cancer: II. Squamous-cell carcinoma.

Authors:  A P Vizcaino; V Moreno; F X Bosch; N Muñoz; X M Barros-Dios; J Borras; D M Parkin
Journal:  Int J Cancer       Date:  2000-05-01       Impact factor: 7.396

8.  Type specific persistence of high risk human papillomavirus (HPV) as indicator of high grade cervical squamous intraepithelial lesions in young women: population based prospective follow up study.

Authors:  Susanne K Kjaer; Adriaan J C van den Brule; Gerson Paull; Edith I Svare; Mark E Sherman; Birthe L Thomsen; Mette Suntum; Johannes E Bock; Paul A Poll; Chris J L M Meijer
Journal:  BMJ       Date:  2002-09-14

9.  The psychosocial impact of human papillomavirus infection: implications for health care providers.

Authors:  P Clarke; C Ebel; D N Catotti; S Stewart
Journal:  Int J STD AIDS       Date:  1996 May-Jun       Impact factor: 1.359

10.  Specific antibody levels at the cervix during the menstrual cycle of women vaccinated with human papillomavirus 16 virus-like particles.

Authors:  Denise Nardelli-Haefliger; Daniel Wirthner; John T Schiller; Douglas R Lowy; Allan Hildesheim; Françoise Ponci; Pierre De Grandi
Journal:  J Natl Cancer Inst       Date:  2003-08-06       Impact factor: 13.506

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.